- AZ-Oxford vaccine safe & efficacious: Interim analysis“ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic Covid-19 in this interim analysis of ongoing clinical trials,” the Lancet said.
- AstraZeneca-Oxford vaccine still under review: UK drug regulatorThe subject expert committee in India is awaiting a nod from the UK's regulator to sign off on the marketing authorisation for SII to deliver the vaccines in India.
- The curious case of AstraZeneca-Oxford vaccineThe company announced that in a small subgroup of the trial participants the vaccine showed better efficacy when administered a half dose first and a full dose after a month. This announcement triggered a series of questions on the company’s trial protocol.
- 'So pleased' - Britain gives first dose of Oxford/AstraZeneca vaccine to dialysis patientPinker, a retired maintenance manager, paid tribute to the scientists who had developed the shot, saying he was looking forward to celebrating his wedding anniversary.
- Covid-19: Govt may get Oxford shots in Jan-Feb, at 50% of MRPIndia is likely to get the first lot of anti-Covid shots in late January-early February. This will be possible as India plans to give Serum Institute of India emergency use approval for the Oxford-AstraZeneca vaccine candidate soon after it gets similar approval in the UK. The government, which will make bulk purchases, has also negotiated a better price — almost half that of the likely MRP of Rs 500-600 for the two-shot vaccine.
- AstraZeneca/Oxford vaccine: Five things to know about landmark UK vaccineThe vaccine is "safe and effective", according to data published by The Lancet medical journal on December 8, with only one of the of the 23,754 volunteers who participated in the trials experiencing "possibly-related severe side effects".
- UK asks regulator to assess AstraZeneca-Oxford vaccine amid questionsU.K. Health Secretary Matt Hancock said he had asked the Medicines and Healthcare Products Regulatory Agency to determine whether the vaccine "meets rigorous safety standards."
- Covid-19: Oxford vaccine likely to be first to get India's nod for emergency useWith preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is looking at the UK, which sources believe may give its nod to the Oxford COVID-19 vaccine next week, before deciding on giving emergency use authorisation to the Serum Institute that is manufacturing the shots.Covid-19: Oxford vaccine likely to be first to get India's nod for emergency use
- European Union regulator gets request to approve AstraZeneca-Oxford COVID-19 vaccineIn a statement Tuesday, the EU regulator said it has received a request for the vaccine to be green-lighted under an expedited process and that it could be approved by Jan. 29 during an EMA meeting, "provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete."
- Covid-19: Serum Institute seeks emergency authorisation for Oxford vaccine Covishield in IndiaThe Serum Institute of India on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for the Oxford COVID-19 vaccine in the country citing unmet medical needs due to the pandemic and in the interest of the public at large, official sources said.Covid-19: Serum Institute seeks emergency authorisation for Oxford vaccine Covishield in India
- 3 Covid vaccines’ efficacy higher than flu shotsAnthony Fauci, top infectious disease expert in the US, had said the over 90% efficacy of Pfizer vaccine candidate ‘is just extraordinary’ and would have a “major impact” going ahead.
- Covishield and Covaxin: All you need to know about the DCGI-approved vaccinesET rounds up facts and some questions on Covishield and Covaxin, approved by DCGI on Sunday
- India's approval of homegrown vaccine criticised over lack of dataThe government also approved the use of a vaccine developed by AstraZeneca and Oxford University which will be the lead vaccine in India's immunisation programme until other shots are approved.
- AstraZeneca-Oxford vaccine safe, Indian trials progressing smoothly: Serum InstituteVaccine major Serum Institute of India on Thursday said the Covid-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly with strict adherence to all protocols.
- Oxford vaccine: Kiran Mazumdar-Shaw seeks quick regulatory processing after UK nodShe cited reports according to which the UK's medicines and healthcare products regulatory agency (MHRA) is likely to grant EUA by mid December. A couple of weeks later, she said, the drugs controller general of India (DCGI) could allow it for emergency use in India.
- Hopefully DCGI will give EUA for Oxford's vaccine immediately after MHRA nod: Mazumdar-ShawOn Monday, AstraZeneca had said one dosing regimen showed vaccine efficacy of 90 per cent when the vaccine was given as a half-dose followed by a full dose at least one month apart, while another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart.
- Covid-19: Decades of work, and half a dose of fortune, drove Oxford vaccine successWhile skill and hard work drove development, AstraZeneca said it was a minor mistake that made the team realise how they could significantly boost the shot's success rate, to as much as 90% from around 60%: by administering a half dose, followed by a full dose a month later.
- Vaccinators line up as Oxford/AstraZeneca jab on brink of approval in UKThe vaccine, which is being produced by bio-pharmaceutical giant AstraZeneca and also has a tie-up with the Serum Institute of India, is being evaluated by the UK's independent Medicines and Healthcare products Regulatory Agency (MHRA) after the final cut of data was submitted by the government last Monday.
- India likely to approve AstraZeneca vaccine by next week, could become 1st country to do soIndia, the world's biggest vaccine-making country, wants to start inoculating its citizens next month and is also considering emergency use authorisation applications for vaccines made by Pfizer Inc and local company Bharat Biotech.
- Vaccination for COVID-19 will be voluntary: Health ministryThe ministry further stated that it was advisable to receive a complete schedule of the anti-coronavirus vaccine irrespective of past history of infection with COVID-19 as this will help in developing a strong immune response against the disease.
- Phase-III trial of Oxford vaccine to begin in Pune next weekThe SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford.
- Serum Institute of India officially halts the trial of Astrazeneca-Oxford vaccine in India"We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following DCGI's instructions and will not be able to comment further on trials", said Adar Poonawala, CEO of Serum Institute of India in a statement.
- View: Hope for vaccine has to be built without over-promisingGovernment's communication on the vaccine has to be clear and transparent - all certainties and uncertainties have to be shared with people.
- AstraZeneca faces more vaccine questions after manufacturing errorWhile an announcement Monday by Astra and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the U.K. partners have sparked worries about whether regulators would clear it. In a later statement, Oxford said a difference in manufacturing processes led to some participants being given a half dose instead of a full one.
- View: We may see a new global medical paradigm that ensures fair access to medicineshe way the global scientific community has come together to focus on ensuring affordable access to new vaccines and therapies for humanity is one of the silver linings of the current crisis.
- Evidence of coronavirus vaccines working in a 'half-measure' takes experts by surpriseSarah Gilbert, professor at Oxford's Nuffield Department of Medicine, said the better result with a smaller initial dose could be because this better "mimics what happens in a real infection".
- Adar Poonawalla 'delighted' at low-cost Covishield vaccine announcement; Mahindra says it's time to get the show on the roadIndia Inc sounded quite optimistic about the Monday announcement.
- Some signs AstraZeneca vaccine durability could be a year: Chief investigator"We don't know yet if this virus will be mutating away from the immune response," the Oxford vaccine group's director Andrew Pollard told reporters at a briefing, adding: "There is no evidence of that yet."
- Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virusSpeaking in a briefing, Andrew Pollard, director of the Oxford Vaccine Group, said it is hard to explain the different efficacy rates between the AstraZeneca/Oxford shot and the other vaccines developed by Pfizer and BioNTech and one by Moderna.
- 'Really good news': British Health Secretary Matt Hancock welcomes Oxford/AstraZeneca vaccine results"These figures ... shows that the vaccine in the right dosage can be up to 90% effective," British Health Secretary Matt Hancock told Sky News, after an announcement from AstraZeneca.
- Serum Institute of India to start phase II trials of Oxford vaccine this weekPhase I human trials were completed in the UK. In India, the volunteers will be administered two doses of the potential vaccine. Thereafter, four weeks apart, its safety and immunogenicity will be assessed.
- Oxford Covid vaccine shows strong immune response in older adultsCovid-19 vaccine being developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University produced a strong immune response in older adults, raising hopes that it can protect the age groups most at risk from the virus.Oxford Covid vaccine shows strong immune response in older adults
- Oxford's COVID-19 vaccine trial results 'definitely' before Christmas - investigatorAsked if it was too early to say whether the vaccine, which is licensed to AstraZeneca, stops disease developing, Andrew Pollard, director of the Oxford Vaccine Group, said: "We haven't quite got to that point yet. We're obviously not going to rush that."
- Oxford University Covid-19 vaccine ‘encouraging' for older age groupsThe findings published in ‘Lancet' on Thursday based on 560 healthy adult volunteers shows that the ChAdOx1 nCoV-19 vaccine is “safe and well-tolerated” with a lower reactogenicity profile in older adults than in younger adults, meaning the older age groups could build immunity to the disease.
- Covid-19: India to start late stage clinical trials of Oxford vaccineThe Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford University. According to the World Health Organization (WHO), a number of vaccines are now in phase-3 clinical trials. Covid-19: India to start late stage clinical trials of Oxford vaccine
- AstraZeneca CEO says COVID-19 vaccine may be ready by end of year despite pause in trialsEarlier this week, the UK-Swedish company reportedly froze the trials after discovering that one participant was sick with transverse myelitis. This condition results in the inflammation of parts of the spinal cord and may be caused by infections, among other things.
- Serum Institute of India gets approval to start human trials for Oxford vaccineEarlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its protocol for the clinical study. The subject expert committee (SEC) had recommended eight amendments to be made to the firm's proposal to conduct Phase-II and -III trials.
- India health authorities betting on AstraZeneca, Bharat Biotech vaccines“India will have to focus on the indigenous vaccines and the AstraZeneca-Oxford vaccine. These vaccines are being tested in the India population and this is a major advantage over any other potential candidate,” said a senior government official.
- WHO on Oxford vaccine trials: Results are positive but a long way to goIn what could be termed as the biggest breakthrough of the year in the fight against the novel coronavirus pandemic, preliminary results showed Oxford/AstraZeneca COVID-19 vaccine candidate is safe and induced immune response. WHO gives its take on the Oxford vaccine trials, says that the results are positive but have a long way to go. WHO on Oxford vaccine trials: Results are positive but a long way to go
- Serum Institute of India to apply for local trials on Oxford's vaccine by AugustSII, the largest vaccine manufacturer in the world, has tied up with AstraZeneca to manufacture the Covid-19 vaccine. SII’s vaccine candidate is undergoing a bio safety trial at the government's Central Drug Laboratory (CDL), Kasauli.
- CCEA approves Rs 1,810-cr investment for 210 MW hydropower project in HimachalThe Union Cabinet on Wednesday approved a proposal to invest Rs 1,810 crore for 210 MW Luhri Stage-I hydropower project on river Satluj in Himachal Pradesh. "The Cabinet Committee on Economic Affairs (CCEA) chaired by Prime Minister Narendra Modi has approved the investment of Rs 1,810.56 crore for 210 MW Luhri Stage-I Hydro Electric Project located on river Satluj which is situated in Shimla and Kullu districts of Himachal Pradesh," an official statement said.CCEA approves Rs 1,810-cr investment for 210 MW hydropower project in Himachal
- India has gained rights for vaccines to cover 50% of population: StudyMost of the rich countries have already purchased 3.8 billion doses of yet-to-be-approved Covid-19 vaccines, with an additional 5 billion doses reserved or under negotiation, according to data compiled by Duke Global Health Innovation Center, which looked at advance purchase agreements from across the world.
- Astra Zeneca-Oxford vaccine trial pause a ‘Wake-up Call’, Says WHODays after Astra Zeneca said it has paused trials of its experimental coronavirus vaccine, the World Health Organization’s (WHO) chief scientist asserted that it a ‘wake-up call’ to recognize that there are ups and downs in clinical development and that we have to be prepared. However, researchers should not be discouraged as these things happen, said Soumya Swaminathan, while addressing a virtual briefing from Geneva.Astra Zeneca-Oxford vaccine trial pause a ‘Wake-up Call’, Says WHO
- COVID-19 vaccine: Phase II trial of Oxford vaccine begins at Pune hospitalThe second phase trial of COVID-19 vaccine developed by Oxford University, which would be manufactured by Serum Institute of India, began here with the vaccine candidate administered to two volunteers at Bharati Vidyapeeth Medical College. Dr Sanjay Lalwani, Medical Director of Bharati Vidyapeeth Medical Hospital and Research Centre, said that five volunteers were tested for RT-PCR and antibodies and reports of three showed they have anti-bodies and vaccine was administered to two volunteers.COVID-19 vaccine: Phase II trial of Oxford vaccine begins at Pune hospital
- Phase II human trial of Oxford vaccine begins in Pune, two get first shotTwo male volunteers were administered the vaccine at Bharti Vidyapeeth's Medical College and Hospital, a senior office-bearer of the hospital said.
- Covid-19: Oxford vaccine's late stage trials to start in a week in India, says ICMRDirector General of Indian Council of Medical Research, Dr Balram Bhargava on August 04 stated that Oxford vaccine, being manufactured by Serum Institute of India, got approval for phase 2 and 3 clinical trials which are starting within a week at 17 sites. Earlier, the Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford vaccine.Covid-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR
- Panel recommends Serum Institute's name for phase 2, 3 human clinical trials of Oxford vaccine candidateThe recommendations of the committee at the Central Drugs Standard Control Organisation have been sent to the Drugs Controller General of India for approval.
- Serum Institute asked to resubmit trial protocol for Oxford vaccine; eight changes suggestedSII's Oxford vaccine is one of the front runners in the fight against Covid-19. On July 20, researchers at the University of Oxford published their data from Phase 1 and 2 trials of the vaccine candidate. The researchers said the trials involving 1,077 healthy adults found that the vaccine induced strong antibody and T-cell immune responses up to day 56.
- AstraZeneca pauses COVID-19 vaccine trial in UK due to unexplained illness of participantUK-based biopharma giant AstraZeneca has said that the phase 3 testing of its COVID-19 vaccine being developed with Oxford University has been put on hold, due to a suspected serious adverse reaction in a participant in the United Kingdom. The vaccine, which AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization (WHO) as probably the world's leading candidate and the most advanced in terms of development.AstraZeneca pauses COVID-19 vaccine trial in UK due to unexplained illness of participant
- AstraZeneca's COVID-19 vaccine reaches phase 3 clinical trials in US, says TrumpAstraZeneca is one of the leaders in the race to develop COVID-19 vaccine. Other companies that have COVID-19 vaccines in phase 3 trials include Moderna Inc and Pfizer Inc.
- Global Markets: Dollar falls, European shares rise as markets buoyed by vaccine hopesAfter the STOXX 600 saw its biggest daily gain in almost two weeks on Monday, the bullish mood continued throughout the New York and Asian sessions.
- Oxford candidate the first Covid vaccine likely to be available in India by end of yearIt is believed that the two local candidates — which are in early stages of human trials — will enter the market with a lag of a few weeks as compared to the Oxford candidate.
- AstraZeneca & Serum Institute of India sign licensing deal for 1 billion doses of Oxford vaccineThe British drug maker also reached a $750m agreement with Coalition for Epidemic Preparedness Innovation (CEPI) and Gavi to support the manufacturing, procurement and distribution of 300 million doses of the potential vaccine, with delivery starting by the end of the year.
- Fresh US stimulus would matter, not the EU package: Manish Singh'The recent rally that we have seen in tech stocks, in Nasdaq and the stocks just jumping way too ahead suggest we might be in for a short-term shakeup. '
- Oxford University Coronavirus vaccine: Why it raises hopeInitial study shows that the Oxford-AstraZeneca vaccine for Covid-19 triggers antibody response and is safe. ET’s Divya Rajagopal gives an in-depth analysis of the vaccine which will go on trial in India soon. WatchOxford University Coronavirus vaccine: Why it raises hope
- Airborne transmission of Covid possible, wear masks in enclosed spaces, cautions CSIRAmid recent acknowledgement from the World Health Organisation (WHO) over emerging evidence of airborne spread of the novel coronavirus, the head of India’s premier R&D body has said that airborne transmission of SARS-CoV-2 is indeed a “distinct possibility” and suggested wearing masks even in “enclosed” spaces.
- India's Covid vaccine landscape: Here is a look at leading candidatesAs global vaccine companies race up for covid-19 vaccine, Indian companies though late in the launch are catching up. The following companies are leading the Indian vaccine landscape for Covid-19.India's Covid vaccine landscape: Here is a look at leading candidates
- Prince William pays a visit to Oxford's coronavirus vaccine development facilitiesThe royal looked at a laboratory where samples from the clinical trial were being examined by researchers.
- AstraZeneca agrees to make COVID-19 vaccine for EuropeAstraZeneca plans to begin delivering the vaccine to European countries by the end of this year under the agreement with the Inclusive Vaccine Alliance, formed this month by France, Germany, Italy and the Netherlands.
- Oxford university begins enrolling over 500 volunteers for coronavirus vaccine trialThe researchers, working in an “unprecedented” vaccine development effort to prevent COVID-19, said they have started screening healthy volunteers (aged 18-55) from Friday for their upcoming trial in the Thames Valley Region of England. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 or COVID-19 spike protein is already in production.
- AstraZeneca plans 2 million doses a week of COVID-19 vaccine for UK: ReportsWhile AstraZeneca says it expects 2 million doses of the Oxford University vaccine to be ready each week in just over a fortnight, Pfizer BioNTech said the number of doses it has now sent to the UK is "in the millions".
- WHO asks Serum Institute of India for Covishield trial data to begin global supplySerum Institute of India is one of the manufacturers that has signed up to supply up to 400 million doses of vaccines to the Covax Facility. In the first quarter, the company is expected to supply 200 million doses of the AstraZeneca/Oxford vaccine which it has developed in India and branded as Covishield.
- Modi to interact with chief ministers on Monday over coronavirus situation, vaccine roll-outThis will be Modi's first interaction with chief ministers following the recent approval of two coronavirus vaccines for restricted emergency use by India's drug regulator.
- Covid-19: USFDA warns against tweaking vaccine dosageSuggestions to tweak dosage strategy to overcome a supply crunch are not rooted in solid evidence and hence such a move could put public health at risk, US Food and Drug Administration commissioner Stephen M Hahn said on Monday night.
- India may have 500 million Covid-19 vaccine doses by MarchCompanies such as Zydus Cadila, Bharat Biotech, Dr Reddys-Gamaleya Institute, Serum Institute-AstraZeneca and Gennova are expected to submit their safety and efficacy data for approval with the drug regulator.
- SII can supply 10m doses to govt in January: Adar PoonawallaThe company is ready to start rolling out supplies of its Covishield vaccine in a week’s time, Poonawalla said. SII is waiting for a formal procurement contract for the vaccine from the Indian government with regard to pricing and distribution.
- Oxford COVID-19 vaccine may become the first to get Indian regulator's nod for emergency useSerum Institute of India (SII) last week also had submitted some additional data required by the Drug Controller General of India (DCGI), the sources said.
- Serum Institute of India ready for Covid-19 vaccine rollout: OfficialSII has already manufactured around 50 million doses of its Covid vaccine called Covishield, which is based on the technology from drugmaker AstraZeneca and Oxford.
- Approval for vaccines accelerates India's journey to be COVID-free, says ModiIn a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.
- India in touch with UK drug officials on Oxford Covid-19 vaccine: Vaccine Task Force Committee“India’s drug regulator is in touch with UK drug authorities on the approval progress of the AZ/Oxford vaccine trial,” Vinod Paul, head of the Vaccine Task Force Committee, said on December 12 at a meeting organised by Ficci.
- Oxford COVID-19 vaccine trial results due this year, trial chief says"I'm optimistic that we could reach that point before the end of this year," chief trial investigator for the vaccine, Andrew Pollard said of presenting trial results this year. Asked if the vaccine would be ready by Christmas he said: "There is a small chance."
- 5 dead in Serum Institute fire; Covishield facility unaffectedThe building where the fire broke out is part of the under-construction site of the Serum facility and is one km from the Covishield manufacturing unit, sources said.
- Centre has not banned export of any COVID-19 vaccine: Union health secretaryResponding to a question during a press briefing on Tuesday, Union Health Secretary Rajesh Bushan said, "The Union government has not banned the export of any one of the COVID-19 vaccines and this should be absolutely clear."
- DCGI finds no link between Covid vaccine shot and 'adverse' reaction in Chennai volunteer during trial: SourcesThe DCGI arrived at the conclusion on Wednesday based on the recommendations of an independent expert committee which has also opined that compensation should not be paid to the volunteer, they said.
- Serum says made 40 mn doses of AstraZeneca's COVID vaccine, to make Novavax shot soonSerum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca's candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.
- Global partnership COVAX secures two billion COVID-19 vaccine dosesCOVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, announced on Friday that it had arrangements in place to access nearly two billion doses of COVID-19 vaccine candidates on behalf of 190 participating economies.
- 2020's parting shot: India to roll out COVID-19 vaccine in January"India is a part of 'COVAX'. We will keep giving 50 per cent of everything we make to India and to COVAX at the same time. India has such a large population that we will probably end up giving the majority of those 50 million doses to India first," Poonawalla said.
- India will be in a position to roll out vaccines once the licensure comes: VK PaulThere is no pressure on India’s regulator to take decision on the grant of market authorisation to the potential Covid-19 vaccine one way or the other and the decision will be made on scientific principles in a matter of days, Niti Aayog member VK Paul said.
- Oxford/AstraZeneca in ‘mix-match' COVID-19 vaccine trial with Russia's SputnikThe two sets of experts are to join forces to explore if a combination of the two jabs, both using a benign virus called adenovirus, could prove effective in offering people long-term protection against COVID-19.
- AstraZeneca COVID-19 shot candidate shows promise among elderly in trialsThe data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70 - who are at higher risk of serious illness and death from COVID-19 - could build robust immunity to the pandemic disease, researchers said.
- Oxford Covid-19 vaccine doing ‘everything expected', independent study findsThe experts say that the novel analysis provides even greater clarity and detail about how the vaccine successfully provokes a strong immune response.
- Speedy distribution of COVID-19 vaccine a major challenge for global govts: WHO expertsThe scientists said it is equally important to ensure sustained surveillance, tracing, test and treat. "It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries," they wrote in an article for Manorama Yearbook 2021.
- In Maharashtra, many netas want vaccine firstDistrict and civic officials told ET they are facing pressure from politicians to include their names as well as those of their family members in the lists of frontline personnel being prepared across the state to be administered the vaccine on priority as soon as it is authorised for use.
- 'Reason to believe effective vaccine for general public in India to be available by Apr 2021'The Oxford vaccine is being risk manufactured by the Serum Institute of India (SII), in order to be widely available to people in large quantities as and when the regulator passes it.
- Task force set up in Maharashtra to manage Covid-19 vaccine distribution: Uddhav ThackerayThe Chief Ministers Office (CMO) later tweeted that Thackeray also informed Modi about various steps the Maharashtra government has taken to curb the spread of the novel coronavirus in the state.
- After varied efficacy data, AstraZeneca to conduct fresh clinical trials of COVID-19 vaccineAstraZeneca/Oxford said this week it would assess why its vaccine candidate generated better efficacy at a lower dose. The statement came as the British-Swedish drug maker AstraZeneca started rolling submission of data to regulators across the world, while also battling perception about the varied efficacy data from the trial of the vaccine developed jointly with the University of Oxford.
- Oxford Covid trial will look at interim Phase III data after 53 infections: InvestigatorThe Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa.
- Committed to engaging with Indian govt to make vaccine available in country: PfizerThe UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19 with the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA)granting a temporary authorisation for its emergency use.
- Covid vaccine rollout urgent as new strains take holdThe European Medicines Agency (EMA) on Wednesday approved the US-made Moderna vaccine, having already given a green light December 27 to one made by Pfizer/BioNTech for use in the European Union.
- Indian vaccine makers - Serum and Gennova - set to host over 20 foreign diplomats this weekThe move comes as the Indian government thinks that it has sufficient doses of vaccine for its population and can also supply to other nations that might be left out in the Covid-19 vaccine race as countries in Europe and US secure their own doses, said an official.
- DCGI seeking more data for authorisation won't impact vaccine roll-out: Govt"This situation was factored-in from before as it is emergency use authorisation. There should be more than reasonable satisfaction about the safety, immunogenicity and effectiveness of the vaccine," NITI Aayog member (health) Dr V K Paul said.
- Oxford/AstraZeneca vaccine expands to GP services in UK“The biggest vaccination programme in NHS (National Health Service) history is already off to a strong start with around 1 million people already vaccinated against coronavirus – this is a credit to our exceptional NHS staff,” said Dr Nikki Kanani, GP and NHS medical director for primary care.
SubscribeGet APP
- Nifty13,962.85-276.05Sensex47,404.53-943.06
- USD/INR72.81-0.14
